Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
• 作者

  Alsadhan Anfal A.; Cheung Jean; Gulrajani Michael; Cook Erika M.; Pittaluga Stefania; Davies-Hill Theresa; Izumi Raquel; Sun Clare C.; Covey Todd; Wiestner Adrian; Herman Sarah E. M.;

  展开▼
• 作者单位

  NHLBI Hematol Branch NIH Bldg 10 Bethesda MD 20892 USA;

  Acerta Pharma San Francisco CA USA;

  Acerta Pharma San Francisco CA USA;

  NHLBI Hematol Branch NIH Bldg 10 Bethesda MD 20892 USA;

  NCI Lab Pathol Ctr Canc Res NIH Bethesda MD 20892 USA;

  NCI NIH CCR Pathol Lab Bethesda MD 20892 USA;

  Acerta Pharma San Francisco CA USA;

  NHLBI Hematol Branch NIH Bldg 10 Bethesda MD 20892 USA;

  Acerta Pharma San Francisco CA USA;

  NHLBI NIH Bldg 10 Bethesda MD 20892 USA;

  NHLBI Hematol Branch NIH Bldg 10 Bethesda MD 20892 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词